Unknown

Dataset Information

0

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

ABSTRACT: High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

SUBMITTER: Bowtell DD 

PROVIDER: S-EPMC4892184 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell David D DD   Böhm Steffen S   Ahmed Ahmed A AA   Aspuria Paul-Joseph PJ   Bast Robert C RC   Beral Valerie V   Berek Jonathan S JS   Birrer Michael J MJ   Blagden Sarah S   Bookman Michael A MA   Brenton James D JD   Chiappinelli Katherine B KB   Martins Filipe Correia FC   Coukos George G   Drapkin Ronny R   Edmondson Richard R   Fotopoulou Christina C   Gabra Hani H   Galon Jérôme J   Gourley Charlie C   Heong Valerie V   Huntsman David G DG   Iwanicki Marcin M   Karlan Beth Y BY   Kaye Allyson A   Lengyel Ernst E   Levine Douglas A DA   Lu Karen H KH   McNeish Iain A IA   Menon Usha U   Narod Steven A SA   Nelson Brad H BH   Nephew Kenneth P KP   Pharoah Paul P   Powell Daniel J DJ   Ramos Pilar P   Romero Iris L IL   Scott Clare L CL   Sood Anil K AK   Stronach Euan A EA   Balkwill Frances R FR  

Nature reviews. Cancer 20151101 11

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015. ...[more]

Similar Datasets

Unknown Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.
| S-EPMC4967013 | biostudies-literature
Unknown Prognostic gene expression signature for high-grade serous ovarian cancer.
| S-EPMC7484370 | biostudies-literature
Unknown The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
| S-EPMC3609073 | biostudies-literature
Unknown A single-cell landscape of high-grade serous ovarian cancer.
| S-EPMC7723336 | biostudies-literature
Unknown PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
| S-EPMC5854713 | biostudies-literature
Unknown First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
| S-EPMC7270049 | biostudies-literature
Unknown IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer.
| S-EPMC7377165 | biostudies-literature
Unknown No evidence for PALB2 methylation in high-grade serous ovarian cancer.
| S-EPMC3636006 | biostudies-literature
Unknown Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.
| S-EPMC7226118 | biostudies-literature
Unknown Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer.
| S-EPMC8125626 | biostudies-literature